(Reuters) - Acorda Therapeutics Inc said Actavis Plc plans to market a generic version of Acorda’s multiple sclerosis treatment, Ampyra.
Ampyra, which was approved in January 2010, had net sales of $72.5 million in the first quarter ended March 31.
Acorda said Actavis has submitted a marketing approval application with the U.S. Food and Drug Administration for a generic version of the drug.
Acorda said it intends to vigorously defend its intellectual property rights.
Reporting By Penumudi Amrutha; Editing by Sriraj Kalluvila